108605
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
乌纳利珠单抗治疗霍普金斯连续性肢端皮炎：1 例病例报告及文献综述
Authors Yao Y, Ma Y, Zhong H, Guo F, Zhu J, Wu Y, Tang S
Received 11 July 2025
Accepted for publication 6 September 2025
Published 23 September 2025 Volume 2025:15 Pages 471—478
DOI https://doi.org/10.2147/PTT.S552600
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Enzo Errichetti
Yi Yao,1– 3,* Yingming Ma,1– 3,* Huajie Zhong,1– 3,* Feiying Guo,1– 3 Jiling Zhu,1– 3 Yuan Wu,1– 3 Shunli Tang1– 3
1Department of Dermatology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, People’s Republic of China; 2Department of Dermatology, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, People’s Republic of China; 3Department of Dermatology, Affiliated Huzhou Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Shunli Tang, Department of Dermatology, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, No. 1558, Sanhuan North Road, Huzhou, 313000, People’s Republic of China, Tel +86-572-2555321, Email tangshunli@zju.edu.cn
Abstract: Acrodermatitis continua of Hallopeau (ACH) is a rare pustular psoriasis subtype, characterized by recurrent sterile pustules on digits, progressive nail deformation and atrophy. ACH is often refractory to different therapeutic modalities, presenting challenges in clinical practice. Emerging evidence indicates that elevated IL-17 levels modulate keratinocyte proliferation and immune cell infiltration, contributing to ACH pathogenesis and representing a promising therapeutic target. Herein, we presented a case of ACH successfully treated with vunakizumab, China’s first self-developed anti-IL-17A monoclonal antibody, and reviewed publications reporting IL-17 targeted therapies for ACH, highlighting the potential benefit of IL-17 targeted therapy in ACH management.
Keywords: acrodermatitis continua of hallopeau, pustular psoriasis, interleukin-17, vunakizumab
1Department of Dermatology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, People’s Republic of China; 2Department of Dermatology, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, People’s Republic of China; 3Department of Dermatology, Affiliated Huzhou Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Shunli Tang, Department of Dermatology, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, No. 1558, Sanhuan North Road, Huzhou, 313000, People’s Republic of China, Tel +86-572-2555321, Email tangshunli@zju.edu.cn
Abstract: Acrodermatitis continua of Hallopeau (ACH) is a rare pustular psoriasis subtype, characterized by recurrent sterile pustules on digits, progressive nail deformation and atrophy. ACH is often refractory to different therapeutic modalities, presenting challenges in clinical practice. Emerging evidence indicates that elevated IL-17 levels modulate keratinocyte proliferation and immune cell infiltration, contributing to ACH pathogenesis and representing a promising therapeutic target. Herein, we presented a case of ACH successfully treated with vunakizumab, China’s first self-developed anti-IL-17A monoclonal antibody, and reviewed publications reporting IL-17 targeted therapies for ACH, highlighting the potential benefit of IL-17 targeted therapy in ACH management.
Keywords: acrodermatitis continua of hallopeau, pustular psoriasis, interleukin-17, vunakizumab